Achaogen (AKAO) Earning Somewhat Favorable Media Coverage, Accern Reports

News coverage about Achaogen (NASDAQ:AKAO) has been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Achaogen earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 46.0974844386471 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

• Achaogen, Inc. (AKAO) closes with a move of -3.36%, Cambrex Corporation (CBM) noted a price change of 1.50% – Stocks Gallery (stocksgallery.com)
• Can Achaogen Inc (AKAO) Thread the Needle? Technical Update – Sparta Review (spartareview.com)
• Achaogen, Inc. (AKAO) Downgraded to “Sell” at BidaskClub (americanbankingnews.com)
• Achaogen, Inc. (NASDAQ:AKAO) to Release Earnings on Monday (americanbankingnews.com)
• Q2 2017 Earnings Forecast for Achaogen, Inc. (NASDAQ:AKAO) Issued By Wedbush (americanbankingnews.com)

Shares of Achaogen (AKAO) traded down 3.73% during midday trading on Tuesday, hitting $18.30. 444,844 shares of the stock traded hands. The company’s market capitalization is $747.48 million. The stock has a 50 day moving average of $22.16 and a 200 day moving average of $22.18. Achaogen has a 1-year low of $3.60 and a 1-year high of $27.79.

Achaogen (NASDAQ:AKAO) last released its earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by $0.39. The company had revenue of $7.46 million for the quarter, compared to analyst estimates of $3.81 million. Achaogen had a negative return on equity of 119.78% and a negative net margin of 212.71%. The business’s revenue for the quarter was up 27.7% compared to the same quarter last year. During the same period last year, the company posted ($0.66) earnings per share. Equities research analysts predict that Achaogen will post ($2.60) earnings per share for the current fiscal year.

AKAO has been the topic of a number of recent research reports. BidaskClub upgraded shares of Achaogen from a “hold” rating to a “buy” rating in a research note on Saturday, July 8th. HC Wainwright initiated coverage on shares of Achaogen in a research note on Thursday, June 15th. They set a “buy” rating and a $29.00 price target on the stock. Stifel Nicolaus reiterated a “buy” rating and set a $31.00 price target (up previously from $28.00) on shares of Achaogen in a research note on Tuesday, May 9th. Zacks Investment Research upgraded shares of Achaogen from a “sell” rating to a “hold” rating and set a $27.00 price target on the stock in a research note on Monday, July 17th. Finally, ValuEngine upgraded shares of Achaogen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $25.98.

WARNING: “[[title]]” was first reported by [[site]] and is owned by of [[site]]. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at [[permalink]].

In related news, CFO Tobin Schilke sold 2,066 shares of the firm’s stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $21.53, for a total value of $44,480.98. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 13.80% of the company’s stock.

Achaogen Company Profile

Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).